Tag - ZVSA

Developments

ZyVersa highlights published data supporting potential of IC 100 for obesity care

ZyVersa Therapeutics (NASDAQ:ZVSA) has highlighted data from a peer-reviewed International Journal of Nanomedicine article demonstrating inflammasome inhibition’s potential to protect pancreatic islet beta cells and...

November 5, 2024

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

Feature

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.

June 13, 2023

Tag - ZVSA

ZyVersa highlights published data supporting potential of IC 100 for obesity care

ZyVersa receives European patent for VAR 200 in kidney disease

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

General

More